



## Australian Technical Advisory Group on Immunisation (ATAGI) 74th meeting, 22 May 2020

Agenda item	Purpose	Discussion and outcomes
<b>1. Welcome and open</b> 1.1. Declarations of interest 1.2. Actions arising from last meeting 1.3. Out of session items	Information	<ul style="list-style-type: none"> <li>Noted.</li> </ul>
<b>2. ATAGI Annual Immunisation Statement</b>	Discuss	<ul style="list-style-type: none"> <li>ATAGI discussed a draft outline for an annual immunisation statement. The intention is to publish this statement at the start of each year to signal gaps and risks in control of vaccine-preventable diseases, and ATAGI’s priorities for immunisation issues in Australia. Topics for the annual statement will be considered throughout the year. The statement will be developed for a broad audience.</li> <li>ATAGI discussed a draft outline for a targeted review — a focused analysis of a particular gap or need in vaccination, including scientific evidence and epidemiological details. The intention is to publish these reviews as required to inform policy decisions.</li> </ul>
<b>3. Report from Meningococcal Working Party</b>	Discuss	<ul style="list-style-type: none"> <li>ATAGI discussed and endorsed advice to the Pharmaceutical Benefits Advisory Committee (PBAC) for upcoming submissions for meningococcal vaccines.</li> </ul>
<b>4. Report from Influenza Working Party</b>	Discuss	<ul style="list-style-type: none"> <li>ATAGI discussed its advice to the PBAC for upcoming submissions for influenza vaccines.</li> </ul>
<b>5. Industry Day reports and discussions</b>	Discuss	<ul style="list-style-type: none"> <li>Each year, ATAGI hosts an Industry Day, during which it invites submissions and presentations from companies on current and emerging vaccines. In light of COVID-19, companies were invited to provide a written report to ATAGI, responding to questions and providing an update on their vaccines.</li> <li>ATAGI reviewed and discussed the documents provided by companies. As occurs every year, ATAGI will write to each company to provide feedback and request any further data or information.</li> </ul>

Endorse: a decision is to be made at this meeting  
 Discuss: a decision is to be made at a future meeting or out of session  
 Information: no decision points at this stage



Agenda item	Purpose	Discussion and outcomes
<b>6. Department Updates</b> 6.1. Therapeutic Goods Administration / Advisory Committee on Vaccines update 6.2. Office of Health Protection update 6.3. Pharmaceutical Benefits Advisory Committee update	Information	<ul style="list-style-type: none"><li>• ATAGI noted that immunisation coverage rates remain high, but may be affected by COVID-19, and the Department is monitoring this closely.</li><li>• ATAGI noted the very high demand for influenza vaccines and the Department's response in securing additional doses, bringing the total number of vaccine doses available for Australians in 2020 to more than 18 million.</li><li>• ATAGI received an update from the Therapeutic Goods Administration (TGA) on the regulatory status of new vaccines, and discussed the processes for TGA evaluation and registration of possible COVID-19 vaccines.</li><li>• ATAGI received an update on current vaccine safety signals of interest and the TGA's activities to respond to those signals.</li><li>• ATAGI noted recent recommendations and upcoming considerations of vaccines by the PBAC.</li></ul>
<b>7. Communicable Diseases Network Australia business</b>	Information	<ul style="list-style-type: none"><li>• ATAGI reviewed data on notifications of influenza, invasive pneumococcal disease and invasive meningococcal disease from the Communicable Diseases Network Australia.</li><li>• ATAGI noted that influenza notifications were substantially lower than in previous years, a possible contributing factor being social distancing in response to COVID-19.</li></ul>
<b>Meeting close</b>		

#### Notes and resources

- ATAGI's membership, terms of reference and conflict of interest information are available on the Department of Health website.
- The digital Australian Immunisation Handbook is available on the Department's website.
- A summary of decisions of key immunisation technical advisory groups of interest report will be available on the NCIRS website.
- Information on NITAGs worldwide is available on the NITAG Resource Centre website.
- Next ATAGI meeting: 18 June 2020, by videoconference. The meeting agenda will be published on the Department of Health website shortly before the meeting.